New drug shows promise for ulcerative colitis in early trial
NCT ID NCT03100864
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This phase 2 trial tested a drug called spesolimab in 8 adults with moderate to severe ulcerative colitis. The main goal was to understand how the drug works in the body, while also checking for safety and any signs of improvement. Participants received the drug for 12 weeks, and researchers looked at changes in genes from gut biopsies and markers of inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
-
Asklepios Kliniken Westklinikum Hamburg
Hamburg, 22559, Germany
-
UZ Leuven
Leuven, 3000, Belgium
-
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Spesolimab (a drug given as an infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe ulcerative colitis.
What could go wrong
This was a very small, early-phase trial with only 8 participants, so results may not apply to everyone. The main goal was to study how the drug works, not to prove it is effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.